Scientific Sessions 2025  /  Biological and Pragmatic Interventions in Heart Failure: From Present to Future  /  Discussant: DAPA-EAT
Logo

American Heart Association

  106
  0

Final ID:

Discussant: DAPA-EAT

  • Fontana, Marianna  ( University College London , London , United Kingdom )
  • Raman, Subha  ( OhioHealth , Columbus , Ohio , United States )
    • Author Disclosures:
    Marianna Fontana: DO have relevant financial relationships ; Consultant:Alnylam, Alexion/Caelum Biosciences, Astrazeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Prothena, Pfizer, Novonordisk, Bayer, Mycardium:Active (exists now) ; Individual Stocks/Stock Options:Mycardium (shares):Active (exists now) ; Individual Stocks/Stock Options:LexeoTherapeutics (share options):Active (exists now) ; Other (please indicate in the box next to the company name):Alnylam, Bridgbio, Astrazeneca, Pfizer.(research grants):Active (exists now) | Subha Raman: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Biological and Pragmatic Interventions in Heart Failure: From Present to Future

Sunday, 11/09/2025 , 08:00AM - 09:15AM

Featured Science

More abstracts on this topic:
Main Results of the Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure (COPILOT-HF) Program – A Pragmatic Randomized Study

Blood Alexander, Mcpartlin Marian, Wagholikar Kavishwar, Caberwal Harjeet, Cannon Christopher, Desai Akshay, Scirica Benjamin, Unlu Ozan, Hassan Shahzad, Nichols Hunter, Ostrominski John, Subramaniam Samantha, Zelle David, Figueroa Christian, Varugheese Matthew

First-in-Human Gene Therapy Trial for Patients with Heart Failure with preserved Ejection Fraction (HFpEF)

Fudim Marat, Rudy Jeffrey, Guerrero Janet, Chan Camie, Patel Manesh, Bavry Anthony, Li Ronald, Sarma Satyam, Macnamara James, Levine Benjamin, Hajjar Roger, Ascheim Deborah, Grodin Justin, Kittipibul Veraprapas, Doukellis Katheryn, Dhimitri Andy, Fitzhugh Robert, Karmat Niharika, Costa Kevin

More abstracts from these authors:
Stiffen Up: Evaluation of HFpEF in the Patient with Cancer

Fontana Marianna, Sarswat Nitasha, Ruberg Frederick

Meet the Trialist: Nexiguran ziclumeran (nex-z, also known as NTLA-2001), an investigational in vivo CRISPR-based therapy for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM): interim report of the Phase 1 study

Fontana Marianna

You have to be authorized to contact abstract author. Please, Login
Not Available